CNS Pharmaceuticals
CNSP
10 hedge funds and large institutions have $652K invested in CNS Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
194% more capital invested
Capital invested by funds: $222K → $652K (+$431K)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more funds holding
Funds holding: 8 → 10 (+2)
15.75% more ownership
Funds ownership: 4.28% → 20.03% (+16%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$366K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$344K |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$101K |
| 4 |
DS
DRW Securities
Chicago,
Illinois
|
+$10.3K |
| 5 |
SIS
Sound Income Strategies
Ft Lauderdale,
Florida
|
+$120 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$74.3K |
| 2 |
Morgan Stanley
New York
|
-$252 |
| 3 |
Citigroup
New York
|
-$18 |
CNSP Hedge Fund Activity: Q4 2025 in Review
10 institutional investors reported a position in CNS Pharmaceuticals (CNSP) for Q4 2025, worth a combined $652K — up 194% from $222K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CNSP positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $366K. The largest seller was UBS Group, cutting an estimated $74.3K.
- 10 institutional investors held CNS Pharmaceuticals (CNSP) as of Q4 2025, up from 8 in Q3 2025.
- Funds reported $652K of CNS Pharmaceuticals stock for Q4 2025, up 194% quarter-over-quarter.
- 4 funds opened new CNS Pharmaceuticals positions in Q4 2025 and 2 closed out, a net change of +2 holders.
- The largest CNS Pharmaceuticals buyer in Q4 2025 was Stonepine Capital Management, an estimated $366K added.
- The largest CNS Pharmaceuticals seller in Q4 2025 was UBS Group, an estimated $74.3K sold.
Based on aggregated 13F filings for Q4 2025.